PT Itama Ranoraya Tbk (IRRA.JK)
IDR 400.0
(-1.48%)
IDR 400.0
(-1.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 32.71 Billion IDR | -56.5% |
| 2022 | 78.97 Billion IDR | -45.98% |
| 2021 | 156.88 Billion IDR | 83.71% |
| 2020 | 82.06 Billion IDR | 78.94% |
| 2019 | 46.11 Billion IDR | 3.06% |
| 2018 | 44.74 Billion IDR | 22.68% |
| 2017 | 33.42 Billion IDR | 2624.71% |
| 2016 | 1.36 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 22.18 Billion IDR | 119.24% |
| 2024 Q1 | 10.44 Billion IDR | 541.78% |
| 2024 Q2 | 12.88 Billion IDR | 14.14% |
| 2023 Q2 | 12.8 Billion IDR | 19.13% |
| 2023 FY | - IDR | -56.5% |
| 2023 Q3 | 9.69 Billion IDR | -24.29% |
| 2023 Q4 | 834.18 Million IDR | -91.4% |
| 2023 Q1 | 10.75 Billion IDR | -37.71% |
| 2022 FY | - IDR | -45.98% |
| 2022 Q4 | 17.26 Billion IDR | 65.69% |
| 2022 Q3 | 10.41 Billion IDR | -54.06% |
| 2022 Q2 | 22.67 Billion IDR | -28.06% |
| 2022 Q1 | 31.52 Billion IDR | 6.59% |
| 2021 Q1 | 27.88 Billion IDR | -59.04% |
| 2021 FY | - IDR | 83.71% |
| 2021 Q4 | 29.57 Billion IDR | -41.89% |
| 2021 Q3 | 50.89 Billion IDR | 17.73% |
| 2021 Q2 | 43.22 Billion IDR | 55.02% |
| 2020 Q2 | 9.07 Billion IDR | 182.02% |
| 2020 Q1 | 3.21 Billion IDR | -91.08% |
| 2020 FY | - IDR | 78.94% |
| 2020 Q4 | 68.08 Billion IDR | 738.9% |
| 2020 Q3 | 8.11 Billion IDR | -10.6% |
| 2019 Q2 | 3.79 Billion IDR | 13.8% |
| 2019 FY | - IDR | 3.06% |
| 2019 Q1 | 3.33 Billion IDR | 0.0% |
| 2019 Q3 | 2.9 Billion IDR | -23.37% |
| 2019 Q4 | 36.07 Billion IDR | 1141.09% |
| 2018 Q1 | 6.1 Billion IDR | 0.0% |
| 2018 FY | - IDR | 22.68% |
| 2017 FY | - IDR | 2624.71% |
| 2016 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 1081.16 Billion IDR | 96.974% |
| PT Kimia Farma (Persero) Tbk | -1223.64 Billion IDR | 102.674% |
| PT Millennium Pharmacon International Tbk | 124.5 Billion IDR | 73.723% |
| PT Soho Global Health Tbk | 538.94 Billion IDR | 93.929% |